In the last decade, there has been increasing interest in the molecules that are expressed on the surface of tumor cells. We used these surface markers specific to cancer to image and or deliver drugs to destroy cancer cells. We have identified monoclonal antibodies (MAb’s) and peptides that bind to Tip 1, GRP78 that are highly expressed in various cancers including lung cancer and glioblastoma. These targeting antibodies and peptides have been validated as an SPECT imaging agent in preclinical mouse models. These have been conjugated to radioisotope to optimize drug delivery to cancer as a potential treatment of human cancer and therapy. Currently we are investigating antibodies that can induce cytotoxicity and liposomes with targeted peptides for targeted therapy.